XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.89

+3.6%

12:32 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (16059)	9/12/2002 6:32:04 PM
From: tom pope	Read Replies (1) of 17367

Biogen sees FDA finishing Amevive review in 6 months Thursday September 12, 6:19 pm ET CAMBRIDGE, Mass., Sept 12 (Reuters) - Biogen Inc. (NasdaqNM:BGEN - News) on Thursday said U.S. regulators would complete a review of its application for psoriasis drug Amevive within six months. The Cambridge, Massachusetts-based company said it expected the application was on track for approval in early 2003 by the U.S. Food and Drug Administration. Psoriasis is a skin inflammation disorder.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next